Considering that in MM: (i) the occurrence of mutations in genes involved in protein translation is frequent [39], (ii) protein biosynthesis is one of the most significantly upregulated biological process in MM vs. normal plasma cells [40], and (iii) c-Myc has a critical role in the biology of MM [41,42,43], we propose the synergistic inhibition of the oncogenic translation program, by the convergent down-modulation of mTORC1 and c-Myc, as one of the main causes of the anti-myeloma effect of the PIM-Pd combination. This evidence concerns the gene MYC and Miyoshi myopathy.